Nöromiyelitis Optika Spektrum Bozuklukları (NMOSD)

Wingerchuk DM, Hogancamp WF, O’Brien PC, et al: The clinical course of neuromyelitis Optica (Devic’s syndrome). Neurology 53(5):1107- 1114, 1999.

Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med (2005) 202(4):473–7.

Hinson SR, Pittock SJ, Lucchinetti CF, Roemer SF, Fryer JP, Kryzer TJ, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology (2007) 69(24):2221–31.

Kleiter I, Gold R. Present and future therapies in neuromyelitis optica spectrum disorders. Neurotherapeutics (2016) 13(1):70–83.

Nicchia GP, Pisani F, Simone L, Cibelli A, Mola MG, Dal Monte M, et al. Gliovascular modifications caused by aquaporin-4 deletion in the mouse retina. Exp Eye Res (2016) 146:259–68.

Wingerchuk DM, Banwell B, Bennett JL, et al: International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurol- ogy 85(2):177-189, 2015

Tenembaum S, Yeh EAGuthy-Jackson Foundation International Clinical C. Pediatric NMOSD: A review and position statement on approach to work-up and diagnosis. Front Pediatr (2020) 8:339.

Jarius S, Aktas O, Ayzenberg I, et al. Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. J Neurol. 2023 Jul;270(7):3341-3368.

Pittock S, Lennon V, Bakshi N, et al. Seroprevalence of aquaporin-4-IgG in a northern California population representative cohort of multiple sclerosis. JAMA Neurol 2014; 71: 1433–1436.

Quek AM, McKeon A, Lennon VA, Mandrekar JN, Iorio R, Jiao Y, et al. Effects of age and sex on aquaporin-4 5. autoimmunity. Arch Neurol. 2012;69(8):1039–43.

Chitnis T, Ness J, Krupp L, et al: Clinical features of neuromyelitis Optica in children: US network of pediatric MS centers report. Neurology 86(3):245-252, 2016.

Tenembaum S, Chitnis T, Nakashima I, Collongues N, McKeon A, Levy M, et al. Neuromyelitis optica spectrum disorders in children and adolescents. Neurology. (2016) 87:S59–66.

Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Wegner B, et al. Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol (2016) 79(2):206–16.

Absoud M, Lim MJ, Appleton R, Jacob A, Kitley J, Leite MI, et al. Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features. J Neurol Neurosurg Psychiatry. (2015) 86:470– 2.

Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the united states: A multicenter analysis. Arch Neurol (2012) 69(9):1176–80.

Kim HJ, Paul F, Lana-Peixoto MA, et al: MRI characteristics of neuromyelitis optica spectrum disorder: An international update. Neurology 84(11):1165-1173, 2015.

Paolilo RB, Hacohen Y, Yazbeck E, et al: Treatment and outcome of aquaporin-4 antibody-positive NMOSD: A multinational pediatric study. Neurol Neuroimmunol Neuroinflamm 7(5).

Lock JH, Newman NJ, Biousse V, Peragallo JH. Update on pediatric optic neuritis. Curr Opin Ophthalmol. 2019 Nov;30(6):418-425.

Apiwattanakul M, Popescu BF, Matiello M, et al. Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol 2010;68:757–761.

Lechner C, Baumann M, Hennes EM, et al. Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease. J Neurol Neurosurg Psychiatry. (2016) 87:897–905.

Camera V, Messina S, Elhadd KT, et al: Early predictors of disability of paediatric-onset AQP4-IgG-seropositive neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry 93(1):101-111, 2022.

Jarius S, Paul F, Franciotta D, et al: Cerebrospinal fluid findings in aqua- porin-4 antibody positive neuromyelitis Optica: Results from 211 lum- bar punctures. J Neurol Sci 306(1-2):82-90, 2011.

Jarius S and Wildemann B. Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathol 2013; 23: 661–683.

Kim SM, Waters P, Woodhall M, et al. Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders. Mult Scler 2013; 19: 1060–1067.

McKeon A, Lennon VA, Lotze T, et al: CNS aquaporin-4 autoimmunity in children. Neurology 71(2):93-100, 2008.

McKeon A, Lennon VA, Jacob A, et al: Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve 39(1):87-90, 2009.

Waters P, McKeon A, Leite M, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 2012; 78: 665–671.

Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007; 130: 1235–1243.

Waters PJ, Pittock SJ, Bennett JL, et al. Evaluation of aquaporin-4 antibody assays. Clin Exp Neuroimmunol 2014; 5: 290–303.

Cohen M, De Sèze J, Marignier R, et al. False positivity of anti aquaporin-4 antibodies in natalizumab-treated patients. Mult Scler 2016; 22: 1231–1234.

Poisson K, Moeller K, Fisher KS. Pediatric Neuromyelitis Optica Spectrum Disorder. Semin Pediatr Neurol. 2023 Jul;46:101051.

Paolilo RB, Rimkus CM, da Paz JA, et al. Asymptomatic MRI lesions in pediatric-onset AQP4-IgG positive NMOSD. Mult Scler Relat Disord 68:104215, 2022

Wingerchuk DM and Lucchinetti CF. Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis. Curr Opin Neurol 2007; 20: 343–350.

Kim W, Park MS, Lee SH, et al. Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity. Mult Scler 2010; 16:1229–1236.

Kim HJ, Paul F, Lana-Peixoto MA, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 2015 Mar 17;84(11):1165-73.

Cortese R, Prados Carrasco F, Tur C, et al. Differentiating multiplesclerosis from AQP4-Neuromyelitis optica spectrum disorder andMOG-Antibody disease with imaging. Neurology. 2023;100:e308–e23.

Mealy MA, Whetstone A, Orman G, Izbudak I, Calabresi PA, Levy M. Longitudinally extensive optic neuritis as an MRI biomarker distinguishes neuromyelitis optica from multiple sclerosis. J Neurol Sci. (2015) 355:59– 63.

Khanna S, Sharma A, Huecker J, et al. Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis. J Neuroophthalmol 2012;32:216–220.

Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006;63:964–968.

Chan KH, Tse CT, Chung CP, et al. Brain involvement in neuromyelitis optica spectrum disorders. Arch Neurol 2011;68:1432–1439.

Marrodan M, Gaitan MI, Correale J. Spinal cord involvement in MS and other demyelinating diseases. Biomedicines. 2020;8:130.

Cassinotto C, Deramond H, Olindo S, Aveillan M, Smadja D, Cabre P. MRI of the spinal cord in neuromyelitis optica and recurrent longitudinal extensive myelitis. J Neuroradiol 2009;36:199–205.

Dubey D, Pittock SJ, Krecke KN, et al. Association of extension ofcervical cord lesion and area postrema syndrome with neuromyelitisoptica spectrum disorder. JAMA Neurol. 2017;74:359–61.

Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805–815.

Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.Neurology. 2015;85:177–89.

Flanagan EP, Weinshenkfer BG, Krecke KN, et al. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrumdisorders. JAMA Neurol. 2015;72:81–7.

Asgari N, Skejoe HP, Lillevang ST, et al. Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population- based, descriptive study. BMC Neurol 2013;13:33.

Kim SM, Kim SJ, Lee HJ, et al. Differential diagnosis of neuromyelitis optica spectrum disorders. Ther Adv Neurol Disord. 2017 Jul;10(7):265-289.

Jarius S, Wildemann B and Paul F. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol 2014; 176: 149–164.

Krupp L, Tardieu M, Amato M, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 2013; 19: 1261–1267.

Koelman D, Chahin S, Mar S, et al. Acute disseminated encephalomyelitis in 228 patients: a retrospective, multicenter US study. Neurology 2016; 86: 2085–2093.

Hyun J, Jeong I, Joung A, et al. Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder. Neurology 2016; 86: 1772–1779.

Zhang L, Wu A, Zhang B, et al. Comparison of deep gray matter lesions on magnetic resonance imaging among adults with acute disseminated encephalomyelitis, multiple sclerosis, and neuromyelitis optica. Mult Scler 2014; 20: 418–423.

Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 2002; 59: 499–505.

Sato D, Nakashima I, Takahashi T, et al. Aquaporin-4 antibody-positive cases current diagnostic criteria for NMO spectrum disorders. Neurology 2013; 80: 2210–2216.

Flanagan EP, Weinshenker BG, Krecke KN, et al. Short myelitis lesions in aquaporin-4-IgG- positive neuromyelitis optica spectrum. JAMA Neurol 2015; 72: 81–87.

Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014; 82: 474–481.

Kitley J, Woodhall M, Waters P, et al. Myelin- oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012; 79: 1273–1277.

Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflamm 2018; 15:134.

Kidd DP, Burton BJ, Graham EM, Plant GT. Optic neuropathy associated with systemic sarcoidosis. Neurology. (2016) 3.

Flanagan EP, Kaufmann TJ, Krecke KN, et al. Discriminating long myelitis of neuromyelitis optica from sarcoidosis. Ann Neurol 2016; 79: 437–447.

Kim SM, Waters P, Vincent A, et al. Sjogren’s syndrome myelopathy: spinal cord involvement in Sjogren’s syndrome might be a manifestation of neuromyelitis optica. Mult Scler 2009; 15: 1062–1068.

Joseph F, Lammie G and Scolding N. CNS lupus: a study of 41 patients. Neurology 2007; 69: 644–654.

Williams JN, Speyer CB, Kreps DJ, et al. Spinal cord syndromes in patients with systemic lupus erythematosus: differentiating lupus myelitis, neuromyelitis optica, and multiple sclerosis. Lupus. (2019) 28:1656–62.

Hoang-Xuan K, Bessell E, Bromberg J, et al. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol 2015; 16: e322–e332.

Lee H, Kim DY, Shin H, et al. Spinal cord involvement in Behçet’s disease. Mult Scler 2016; 22: 960–963.

Al Sawaf A and Berger J. Longitudinally extensive transverse myelitis suspected

for isolated Neuro-Behçet: a diagnostic conundrum. Mult Scler Relat Disord 2015; 4: 395–399.

Kanoto M, Hosoya T, Toyoguchi Y, et al. Brain stem and cerebellar atrophy in chronic progressive neuro-Behçet’s disease. Eur J Radiol 2013; 82: 146–150.

Kikuchi H, Takayama M and Hirohata S. Quantitative analysis of brainstem atrophy

on magnetic resonance imaging in chronic progressive neuro-Behçet’s disease. J Neurol Sci 2014; 337: 80–85.

Parker SE and Pula JH. Neurosyphilis presenting as asymptomatic optic perineuritis. Case Rep Ophthalmol Med 2012; 2012: 621872.

Chilver-Stainer L, Fischer U, Hauf M, et al. Syphilitic myelitis: rare, nonspecific, but treatable. Neurology 2009; 72: 673–675.

Baumann M, Hennes E, Schanda K, et al. Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): extending the spectrum of MOG antibody positive diseases. Mult Scler 2016; 22: 1821–1829.

Chan KH, Lee CY. Treatment of neuromyelitisoptica spectrum disorders. Int J Mol Sci (2021) 22(16):8638.

Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American society for apheresis: The eighth special issue. J Clin Apher (2019) 34(3):171–354.

Abboud H, Petrak A, Mealy M, et al. Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange. Mult Scler. 2016;22(2):185–92.

Stiebel-Kalish H, Hellmann MA, Mimouni M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflamm (2019) 6(4):e572.

Gombolay GY, Chitnis T. Pediatric Neuromyelitis Optica Spectrum Disorders. Curr Treat Options Neurol. 2018 May 2;20(6):19.

Yu HH, Qin C, Zhang SQ, et al: Efficacy of plasma exchange in acute attacks of neuromyelitis Optica spectrum disorders: A systematic review and meta-analysis. J Neuroimmunol 350:577449, 2020.

Siritho S, Nopsopon T, Pongpirul K: Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuro- myelitis Optica spectrum disorders (NMOSD): a systematic review and meta-analysis. J Neurol 268(12):4549-4562, 2021.

Kim SH, Kim W, Huh SY, et al. Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-Aquaporin-4 antibody levels. J Clin Neurol (2013) 9(1):36–42.

Savransky A, Rubstein A, Rios MH, et al. Prognostic indicators of improvement with therapeutic plasma exchange in pediatric demyelination. Neurology (2019) 93(22):e2065–e73.

Shah YD, Eksambe P, Fomani K, et al. Feasibility & safety of plasma exchange in paediatric neuro-immunology: A single center experience. Eur J Paediatr Neurol (2020) 27:94–7.

Bonnan M, Valentino R, Debeugny S, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of nmo spectrum disorders. J Neurol Neurosurg Psychiatry (2018) 89 (4):346–51.

Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the neuromyelitis optica study group (NEMOS). J Neurol. 2014;261(1):1–16.

Zhou Y, Zhong X, Shu Y, et al. course, treatment responses and outcomes in Chinese paediatric neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 2019; 28:213–220.

Banwell B, Tenembaum S, Lennon VA, Ursell E, Kennedy J, Bar-Or A, et al. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology. 2008;70(5):344–52.

Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009;66(9):1128–33.

Chen H, Qiu W, Zhang Q,et al. Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spec-

trum disorder. Eur J Neurol. 2017;24(1):219–26.

Nosadini M, Alper G, Riney CJ, et al. Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder. Neurol Neuroimmunol 66. Neuroinflamm. 2016;3(1):e188.

Ghezzi A, Banwell B, Bar-Or A, et al: Rituximab in patients with pediat- ric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations. Mult Scler 27(12):1814-1822, 2021.

Espiritu AI, Pasco PMD: Efficacy and tolerability of azathioprine for neuromyelitis Optica spectrum disorder: A systematic review and meta- analysis. Mult Scler Relat Disord 33:22-32, 201.

Stankoff B, Waubant E, Confavreux C, et al. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology. 2005;64(7):1139–43.